Trident LifelineShare price, financial results, shareholding and management

BSE SME · TLLGeneric formulations
tridentlifeline.com ↗Live price on BSE ↗ISIN INE0MKA01014 · Lot 600 shares · ₹2.46 lakh
₹410.00
+2.80% on the day
Close · 19 Nov 2026
Valuation
Market cap
₹490 cr
Stock P/E
25.4peers 19.8
Book value
₹83.6
Price to book
4.90
EV / operating profit
-
Market cap to sales
3.80
Returns and growth
ROCE · FY26
21.4%
ROE · FY26
23.4%
ROE, 3-year average
17.7%
Operating margin · FY26
21.8%peers 12.7%
Sales growth, 3 years
59.7%
Profit growth, 3 years
47.6%
Safety
Debt to equity
0.73peers 0.35
Borrowings
₹73 cr
Interest cover
7.6×
Cash from business / op. profit
18%
Debtor days
209
Pledged
0.00%
Ownership and share
Promoter holding
62.46%
Change in promoter holding
0.00 pts
Shareholders
742
52-week high / low
₹442 / ₹230
Dividend yield
0.00%
Face value
₹10

Tap or hover on any figure for what it means. Our arithmetic on reported figures, at the latest close.

Trident Lifeline share price chart

₹410.00+31.41% 1 year

Close on 19 Nov 2026 · +2.76% on the day · Vol 4,800

Daily prices to 19 Nov 2026, adjusted for splits and bonuses. Closing prices only: check the exchange for the live price.

Share price returns

To the close of 19 Nov 2026

1 month
+2.0%
3 months
+46.5%
6 months
+64.8%
1 year
+31.4%
Traded a day, 20 days
₹0.59 cr

Business growth

Sales and net profit, from the reported results

SalesProfit
FY26 on FY25+48%+84%
3 years, a year+60%+48%
Latest half, H2 FY26+52%+81%

About Trident Lifeline: business, products and customers

Trident Lifeline makes and supplies low cost generic medicines, mostly tablets and capsules, to distributors in Africa, Asia and Latin America and to buyers in India, and is adding injectables, medical devices, supplements and personal care products. Its shares trade on BSE SME.

Trident Lifeline, based in Surat, sells generic tablets, capsules, syrups, ointments and dry powders under its own brands and in bulk through merchant exporters. Before a medicine can be sold abroad it must be registered with that country's health authority, a process the company says takes one and a half to three years and is done jointly with the local customer; the company has been building this bank of registrations since its start in 2014.

It runs a hybrid model: part of the output comes from its own and subsidiary plants and part from contract and loan licence manufacturers, with the company buying the raw and packing materials itself. Buying in finished goods keeps capital needs low but leaves a thinner margin than making them, so the mix moves the gross margin; new plants carry fixed costs before they fill, and customer dues have grown fast, which keeps cash from operations far below profit.

Read more about the business

The prospectus named Vaishali Pharma and Chandra Bhagat Pharma as its listed peers. Sales go to distributors, dealers and B2B partners, with domestic sales now close to half the total, and a part of sales goes to two firms in which directors have an interest.

What is new: an injectables plant (TLL Parenterals) and nutraceuticals (TLL Wellness) expected to start earning in FY27, IV cannulas and infusion sets from Trident Mediquip, the YES personal care brand, planning for a cephalosporin facility (TLL Cefa), 50,000 square metres of land bought, and a preferential issue of shares and warrants approved by the board on 5 October 2026.

From the prospectus (September 2022), the FY26 annual report, the May 2026 investor presentation and exchange announcements of October 2026.

Read the deeper study ↓

In its favour

  • Sales have grown very fast: 60% a year over three years.
  • It earns a high return on the money it uses: ROCE 21% in FY26.
  • The promoters own a large part of the company: 62.46%.

To watch

  • First revenue from the TLL Parenterals injectables plant and TLL Wellness nutraceuticals, which the company expects in FY27 (Annual report FY26, p.10).
  • The preferential issue of equity shares and warrants put to shareholders on 27 October 2026 (exchange announcement, 5 October 2026).
  • Conversion of the 2,534 registrations in process into approvals (Annual report FY26, p.16).
  • Whether TNS Pharma, which lost ₹3.0 cr in FY26, moves to profit as its plant fills (Annual report FY26, p.40).
  • Customers take longer to pay than before: 209 days in FY26, against 97 in FY20.

From the company's documents first, then the reported figures read by fixed rules, the same for every company. Facts, not a view on the shares.

Trident Lifeline revenue and profit growth

Half-yearly results · Profit and loss

Sales have grown very fast. Last year profit grew faster than sales, so the company kept more from each rupee of sales.

Sales and net profit, every year, ₹ crore
SalesNet profit
-50050100150Sales, FY20: 5 ₹ cr5Net profit, FY20: -1 ₹ cr-1FY20Sales, FY21: 10 ₹ cr10Net profit, FY21: 1 ₹ cr1FY21Sales, FY22: 22 ₹ cr22Net profit, FY22: 4 ₹ cr4FY22Sales, FY23: 31.7 ₹ cr31.7Net profit, FY23: 6 ₹ cr6FY23Sales, FY24: 44.6 ₹ cr44.6Net profit, FY24: 5.9 ₹ cr5.9FY24Sales, FY25: 87 ₹ cr87Net profit, FY25: 10.5 ₹ cr10.5FY25Sales, FY26: 129 ₹ cr129Net profit, FY26: 19.3 ₹ cr19.3FY26
The latest halves, ₹ crore
SalesNet profit
020406080Sales, H1FY23: 13.8 ₹ cr13.8Net profit, H1FY23: 2 ₹ cr2H1FY23Sales, H2FY23: 17.9 ₹ cr17.9Net profit, H2FY23: 4 ₹ cr4H2FY23Sales, H1FY24: 18.6 ₹ cr18.6Net profit, H1FY24: 3.1 ₹ cr3.1H1FY24Sales, H2FY24: 26.1 ₹ cr26.1Net profit, H2FY24: 2.8 ₹ cr2.8H2FY24Sales, H1FY25: 29.3 ₹ cr29.3Net profit, H1FY25: 4.4 ₹ cr4.4H1FY25Sales, H2FY25: 49.6 ₹ cr49.6Net profit, H2FY25: 6.3 ₹ cr6.3H2FY25Sales, H1FY26: 53.4 ₹ cr53.4Net profit, H1FY26: 7.9 ₹ cr7.9H1FY26Sales, H2FY26: 75.7 ₹ cr75.7Net profit, H2FY26: 11.4 ₹ cr11.4H2FY26

SME companies report every six months. In the latest half, sales were higher than in the same half a year before. Profit grew faster than sales.

Trident Lifeline half-yearly results

SME companies report every six months · ₹ crore

₹ crore · growth on the same half a year before
H1FY23H2FY23H1FY24H2FY24H1FY25H2FY25H1FY26H2FY26
Sales13.8317.8718.5826.0529.2549.6253.3675.67
Expenses11.5013.9414.6221.8222.0540.1841.33·
Operating profit2.323.933.964.247.209.4512.03·
OPM16.8%22.0%21.3%16.3%24.6%19.0%22.5%·
Interest0.180.280.200.400.992.332.11·
Depreciation0.120.240.290.680.703.502.37·
Profit before tax2.154.434.174.536.547.3110.5616.63
Net profit2.023.993.112.834.416.337.8811.44

Trident Lifeline profit and loss

Full years to March, FY20 to FY26 · ₹ crore, consolidated where reported

₹ crore
FY20FY21FY22FY23FY24FY25FY26
Sales5102231.6944.6386.97129.02
Expenses581925.4436.4472.10100.91
Operating profit0136.258.1914.8628.11
OPM-5.0%13.0%12.0%19.7%18.4%17.1%21.8%
Other income0011.162.088.239.27
Interest1000.470.603.984.12
Depreciation0000.360.975.496.07
Exceptional and other items··-1····
Profit before tax-1136.588.7013.6227.19
Tax rate-26.0%0.0%-33.3%8.7%31.7%23.0%28.9%
Net profit-1146.015.9410.4919.32
EPS ₹-2.581.264.946.235.1710.2216.32
Dividend payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%

The years to FY22 come rounded to the nearest crore in the source.

Exceptional and other items: profit before tax beyond operating profit, other income, interest and depreciation, such as one-off items or a share of associates' profit, as reported.

A tax rate above 60% or below zero (FY20, FY22) comes from tax charged on a small or negative profit, as reported.

Trident Lifeline profitability

Margins and returns on capital

Last year the company kept more from each rupee of sales than the year before. It earns a high return on the money it uses.

Operating margin, every year

Per cent of sales kept before interest, depreciation and tax

-10%0%10%20%30%FY20: -5.0%-5.0%FY20FY21: 13.0%13.0%FY21FY22: 12.0%12.0%FY22FY23: 19.7%19.7%FY23FY24: 18.4%18.4%FY24FY25: 17.1%17.1%FY25FY26: 21.8%21.8%FY26
Per cent
FY20FY21FY22FY23FY24FY25FY26
Operating margin-5.0%13.0%12.0%19.7%18.4%17.1%21.8%
Tax rate-26.0%0.0%-33.3%8.7%31.7%23.0%28.9%
ROCE·25.0%50.0%23.1%14.9%18.5%21.4%
ROE··160.0%23.6%12.0%17.8%23.4%
Dividend payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Trident Lifeline debt and cash flow

Balance sheet · Cash flow · Working capital

The company's own money, its net worth, has grown fast. Its loans are smaller than its own money. Last year the business brought in less cash than it showed as profit, so part of the profit is still to be collected. It spent more on assets and investments than the business brought in, and raised the rest from loans or shares. Customers take longer to pay than they did in FY24, which ties up more of the company's money in unpaid bills.

Its own money and its borrowings, ₹ crore
Net worthBorrowings
-50050100Net worth, FY20: -3 ₹ cr-3Borrowings, FY20: 6 ₹ cr6FY20Net worth, FY21: 0 ₹ cr0Borrowings, FY21: 5 ₹ cr5FY21Net worth, FY22: 5 ₹ cr5Borrowings, FY22: 2 ₹ cr2FY22Net worth, FY23: 46 ₹ cr46Borrowings, FY23: 8 ₹ cr8FY23Net worth, FY24: 53 ₹ cr53Borrowings, FY24: 18 ₹ cr18FY24Net worth, FY25: 65 ₹ cr65Borrowings, FY25: 54 ₹ cr54FY25Net worth, FY26: 100 ₹ cr100Borrowings, FY26: 73 ₹ cr73FY26
Cash from the business against net profit, ₹ crore
Cash from the businessNet profit
-20-1001020Cash from the business, FY20: -1 ₹ cr-1Net profit, FY20: -1 ₹ cr-1FY20Cash from the business, FY21: 1 ₹ cr1Net profit, FY21: 1 ₹ cr1FY21Cash from the business, FY22: 0 ₹ cr0Net profit, FY22: 4 ₹ cr4FY22Cash from the business, FY23: -19 ₹ cr-19Net profit, FY23: 6 ₹ cr6FY23Cash from the business, FY24: 2 ₹ cr2Net profit, FY24: 5.9 ₹ cr5.9FY24Cash from the business, FY25: -4 ₹ cr-4Net profit, FY25: 10.5 ₹ cr10.5FY25Cash from the business, FY26: 5 ₹ cr5Net profit, FY26: 19.3 ₹ cr19.3FY26

Bars below the line are cash going out.

Trident Lifeline balance sheet

At each 31 March · ₹ crore

₹ crore
FY20FY21FY22FY23FY24FY25FY26
Equity capital35812121212
Reserves-6-5-334415388
Net worth-305465365100
Borrowings6528185473
Other liabilities3679163763
Total liabilities611146387156236
Fixed assets1113214461
Capital work in progress00054218
Investments00034118
Other assets51013525899149

Trident Lifeline cash flow

₹ crore

₹ crore
FY20FY21FY22FY23FY24FY25FY26
Cash from operations-110-192-45
Cash from investing0-10-10-20-14-37
Cash from financing1-1142111434
Net cash flow0-1113-7-42

Working capital

Days

Days
FY20FY21FY22FY23FY24FY25FY26
Debtor days972483139110116209
Inventory days10434995129156226173
Days payable2022661348794119182
Cash conversion cycle-110744182173224199
Working capital days-121249275205144134

Trident Lifeline peers and competitors

Listed SME companies in the same industry

By sales, Trident Lifeline is number 10 of the 34 listed SME companies in pharmaceuticals & biotechnology.

Each company's latest full year and its latest close; companies the exchange puts in the same industry, whose businesses can differ a good deal. A list, not a comparison of their shares.

CompanyMarket cap ₹ crP/ESales ₹ crProfit ₹ crOp. marginDebt/equity
Mono Pharmacare1644.61660.42.4%1.79
Astonea Labs34168.114859.0%0.74
Influx Healthtech63230.814720.520.3%0.00
Jfl Life Sciences355.51316.48.9%0.47
Trident Lifeline49025.412919.321.8%0.73
Dipna Pharmachem113.512933.9%0.21
Chandra Bhagat Pharma3210.511633.3%0.50
Quest Laboratories15410.31121516.3%0.08
KRM Ayurveda57328.61022030.0%0.00
Sotac Pharmaceuticals10017.31015.817.7%0.64
Accretion Pharmaceuticals21522.289.69.716.7%0.23
Median of the 10 others12719.81236.112.7%0.35

Trident Lifeline shareholding pattern

Promoters, FIIs, DIIs, HNIs and small holders

The promoters own more than half the company, a little less than in the first filing shown. Foreign and Indian funds own a noticeable share. The number of shareholders is about the same.

Promoters
62.46%
-0.53 pts since Dec 24
Foreign investors (FIIs)
4.93%
-1.16 pts since Dec 24
Indian institutions (DIIs)
0.26%
+0.26 pts since Dec 24
Number of shareholders
742
523 in Dec 24

Trident Lifeline shareholding pattern

Per cent of shares, from the patterns filed with the exchange. Tap + to see everyone holding 1% or more in that group. HNIs and small holders show only where the pattern was filed in full.

Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Aug 26
Promoters62.99%63.04%63.04%63.10%64.11%62.86%62.46%62.46%
Foreign investors (FIIs)6.09%6.62%7.21%7.71%7.04%7.24%-4.93%
Indian institutions (DIIs)0.00%0.09%0.39%0.41%0.35%0.27%-0.26%
Number of shareholders523534549554575607742742

Trident Lifeline study: the business from its own documents

Read from 8 of the company's own documents

Trident Lifeline key facts from the filings

Each figure with the document it comes from

Products registered abroad
1,091
Export market registrations at March 2026, with 2,534 more in process across 46 countries.Annual report FY26, p.16
Registrations planned
300 to 400 a year
New filings the company plans each year; each takes one and a half to three years to clear.Annual report FY26, p.8; Investor presentation, May 2026, p.19
Domestic share
49%
Share of FY26 revenue sold in India, up from 30% in FY25; Asia led exports.Annual report FY26, p.16
Tablets and capsules
97%
Tablets gave about 67% and capsules about 30% of FY26 revenue.Annual report FY26, p.16
Gross margin
40.7%
In FY26, down 6.9 points as material costs rose faster than sales; lower overheads lifted the EBITDA margin instead.Annual report FY26, p.16
Show 5 more facts
Capacity in use
40%
Utilisation across the group's plants as stated in the FY26 annual report.Annual report FY26, p.4
Trident Mediquip
₹27.3 cr sales
FY26 turnover of the 59.77% owned medical device arm, with ₹4.3 cr profit after tax.Annual report FY26, p.40
TNS Pharma
₹3.0 cr loss
FY26 loss after tax of the 51% owned tablet and capsule plant, on ₹5.8 cr of turnover.Annual report FY26, p.40
Sales to related firms
₹15.7 cr
Sold in FY26 to Tench Lifesciences LLP and Talon Healthcare LLP, in which directors have an interest.Annual report FY26, p.38; our arithmetic
Customer dues
₹49.3 cr
Standalone trade receivables at March 2026, up from ₹20.4 cr a year earlier.Investor presentation, May 2026, p.30

What the company said, and what happened

The company's own statements, attributed, set against what it later reported; not newboard's estimates

The company says its injectables and nutraceutical businesses should begin contributing revenue from FY27 as their facilities are commissioned and utilisation is built up, that it plans to add 300 to 400 product registrations a year, and that it is planning a cephalosporin facility on newly acquired land. The May 2026 presentation calls the FY27 outlook robust without giving figures. On 5 October 2026 the board approved a preferential issue of equity shares and warrants, to be put to shareholders on 27 October 2026.

FY27Injectables and nutraceuticals startAs the company expects
2,534Registrations in processMarch 2026
27 Oct 2026Meeting on preferential issueAnnounced 5 October 2026

Is it a good business? Six questions

Each answer is about that one question, read from the documents; tap one for the evidence. Not a view on the shares.

Trident Lifeline earns a spread on low cost generic medicines, and its edge is a large stock of country registrations that take years to build.

Its weak spots are thin pricing power, new plants that are not yet full, sales to related firms and customer dues that have grown faster than sales.

WatchCan it set its own prices?It supplies common generic medicines, so it competes on price and could not pass on all of its higher costs last year.
The evidence. Material costs rose 68% against 48% revenue growth in FY26, cutting the gross margin to 40.7%.Annual report FY26, p.16
AverageHow strong is it against rivals?Its registrations are slow for others to copy, but many Indian makers offer the same molecules.
The evidence. The company holds 1,091 registrations with 2,534 in process and says each takes one and a half to three years and requires the plant to be registered first.Annual report FY26, p.16; Investor presentation, May 2026, p.19
WatchWho are its customers?Sales go to distributors and B2B buyers, a few of which have mattered a lot, and part goes to firms linked to directors.
The evidence. The top ten customers gave 58.26% of FY22 sales; in FY26 the company sold ₹15.7 cr to two LLPs in which directors have an interest.Prospectus, p.32; Annual report FY26, p.38
WatchDoes it need a lot of money?Registrations, new plants and customer credit all take cash, and the company keeps raising equity.
The evidence. Standalone receivables rose to ₹49.3 cr from ₹20.4 cr and investing outflows were ₹20.1 cr in FY26; shares were issued in FY26 and a further preferential issue was approved in October 2026.Investor presentation, May 2026, p.30 and p.31; Annual report FY26, p.58; exchange announcement, 5 October 2026
AverageCan it keep finding new work?A long queue of pending registrations and new product lines give room to grow, but approvals clear slowly and the new plants are untested.
The evidence. The company plans 300 to 400 registrations a year; injectables and nutraceuticals are expected to contribute only from FY27, and TNS Pharma lost money in FY26.Annual report FY26, p.4, p.8 and p.40
AverageDo good and bad years swing a lot?Sales have risen every year, but currency moves, registration timing and plant start ups can shift margins.
The evidence. The chairman notes long registration timelines and currency volatility in some markets, and that utilisation of the newer facilities is still modest.Annual report FY26, p.11

Who runs Trident Lifeline?

Promoters, directors and officers; tap a name for the background

HJHardik Jigishkumar DesaiPromoter, Chairman and Executive Director · holds 23.11%

Holds a BCom from South Gujarat University and more than 24 years of experience across the pharmaceutical and textile industries; first joined the board in 2015, rejoined in October 2020 and was named Chairman in June 2022. Oversees the overall management of the company.

Prospectus, p.199; Annual report FY26, p.13 and p.57
SHShravan Harikrishna PatelManaging Director

Holds a Master of Urban and Regional Planning from CEPT University; Managing Director since June 2022 and in charge of procurement, sourcing and supply chain, with eight years in the pharmaceutical industry as the annual report states.

Prospectus, p.199; Annual report FY26, p.13
RCRupaben Chetan JariwalaPromoter and Whole Time Director · holds 5.30%

A commerce graduate with seven years in pharmaceutical business administration, involved in operational planning and organisational development.

Prospectus, p.1; Annual report FY26, p.13 and p.57
MMMayurkumar Mansukhbhai GajeraPromoter · holds 3.98%

Holds an MBA in marketing management and was a Whole Time Director at the time of the IPO, with experience in the pharmaceutical and herbal industry.

Prospectus, p.1 and p.199; Annual report FY26, p.57
AAAshish Anandsingh BafnaExecutive Director and Chief Financial Officer

A fellow chartered accountant with more than 27 years in finance and accounting, diplomas in information system audit and computer assisted audit techniques from ICAI, and registration as an insolvency professional.

Annual report FY26, p.13
MHManiya Hardik DesaiChief Operating Officer

Holds a BBA in marketing from Manipal Academy of Higher Education and eight years in the pharmaceutical industry; was a non executive director at the time of the IPO.

Prospectus, p.199; Annual report FY26, p.13
SKSmita Kiran DavdaIndependent Director

A chartered accountant with more than 23 years in banking and financial services, including senior roles at Yes Bank.

Annual report FY26, p.13
SBSachin BhandariIndependent Director

Holds an MBA and BCom and more than 25 years in the pharmaceutical industry in quality systems, regulatory compliance and digital transformation at UCB Pharma, Boehringer Ingelheim, Sun Pharma, Reckitt Benckiser and GSK.

Annual report FY26, p.13

Trident Lifeline latest news and announcements

Announcements · Documents · Corporate actions

What changed recently

Each half-year is set against the same half a year earlier

  • H2 FY26: sales ₹75.7 cr (+52%), net profit ₹11.4 cr (+81%) on H2 FY25.
  • Shareholding, 31 Aug 2026: promoters unchanged at 62.46%.

Trident Lifeline announcements

20 on record, latest first; each opens the filing on the exchange

Trident Lifeline annual reports, earnings calls and documents

Every document links to its source; “read” marks those this page is built from

Trident Lifeline share split, bonus and dividends

From the corporate actions the company announces on the exchange

No share split, bonus issue or dividend is on record since listing.

Checks we ran on Trident Lifeline's data · 9

Before any number shows, it goes through the same checks. A figure that fails is held back, never shown as if it were right.

  • !The two halves of FY25 as reported add up to sales of ₹78.88 cr, the full year to ₹86.97 cr; one of the filings may have been restated.
  • ✓Balance sheet totals add up for FY25 and FY26.
  • ✓Market cap uses the share count in the latest shareholding pattern (1,19,57,000 shares).
  • ✓The share capital in the FY26 results matches the share count in the shareholding pattern.
  • ✓Promoter and public holdings add up to 100% in every shareholding pattern shown.
  • ✓The two half-years of FY26 add up to the full-year sales.
  • ✓Earnings per share moves in line with profit across the years shown.
  • ✓Revenue and profit are reported for every year shown, FY20 to FY26.
  • iPrices run to the close on 14 Oct 2026, from the exchange's daily figures.

Questions people ask about Trident Lifeline

What does Trident Lifeline do?

Trident Lifeline makes and supplies low cost generic medicines, mostly tablets and capsules, to distributors in Africa, Asia and Latin America and to buyers in India, and is adding injectables, medical devices, supplements and personal care products. Its shares trade on BSE SME.

What is the share price of Trident Lifeline?

₹410 at the close on 19 Nov 2026, from the exchange's daily figures.

What is the market cap of Trident Lifeline?

₹490 cr at the close on 19 Nov 2026, on 1,19,57,000 shares.

What is the P/E of Trident Lifeline?

25.4 times FY26 profit at the close on 19 Nov 2026 (our arithmetic).

What are Trident Lifeline's revenue and profit?

Revenue ₹129 cr and profit after tax ₹19 cr in FY26.

Who are the promoters of Trident Lifeline?

Hardik Jigishkumar Desai, Rupaben Chetan Jariwala, Mayurkumar Mansukhbhai Gajera; promoters held 62.46% at 31 Aug 2026.

What is Trident Lifeline's website?

www.tridentlifeline.com

More SME companies like Trident Lifeline

Other listed SME companies in pharmaceuticals & biotechnology, the closest in size first, each read from its own documents.

Every listed SME company in Pharmaceuticals & Biotechnology →

Built from 3 investor presentations, 3 annual reports, 1 offer document, 1 press release, 20 exchange announcements, 8 shareholding patterns and 7 years of reported results. Every figure carries its source; where the documents are silent, the page says so.